Backlog Backfire: FDA Sees Increase In Pending Generic Applications At Deadline
Executive Summary
The agency was expecting many pending generic drug submissions to be withdrawn because sponsors would not want to pay the one-time backlog fee, but instead saw a substantial increase near the end of FY 2012.
You may also be interested in...
'Bridging' Of Generic Review Goal Dates Makes Progress At US FDA
Assigning official goal dates to ANDAs that hadn't been included in GDUFA began in mid-October and already has lead to approvals.
'Bridging' Of Generic Review Goal Dates Makes Progress At US FDA
Assigning official goal dates to ANDAs that hadn't been included in GDUFA began in mid-October and already has lead to approvals.
There's The Bolus! ANDA Sponsors Race To Avoid User Fee Spike
In a year defined by application surges, more than 200 ANDAs were submitted in September, the last month of fiscal year 2017, likely to avoid paying a much higher application fee instituted Oct. 1.